the identification of low responders to antiplatelet therapy could help reduce these events with more powerful antiplatelet drugs currently under development. Phase III trials with promising new ...

A new study has found that the clot-dissolving drug alteplase can significantly improve stroke recovery even when given up to ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Two common medications that are categorized as blood ... these risks while benefiting from the protective effects of ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

The Cube CYP2C19 test can be used to aid clinicians in determining therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. Genomadix CubeTM CYP2C19 System identifies the CYP2C19 ...